Prodrug for tumor therapy
Scientists of the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-Molar range) as well as a selective tumor therapy through their prodrugs based on the Antibody Directed Enzyme Prodrug Therapy (ADEPT). Selective is achieved by the specific tumor targeting through the antibody. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site through the enzyme, which is coupled to the antibody. While prodrugs have a low cytotoxicity, active drugs show an unbelievable cytotoxicity in the pico-molar range, much higher than actually used Doxorubicin. The drugs could be used equivalent to current chemotherapeutic agents or combined with e.g. a targeting-antibody.
We are now looking for companies, which are interested in licensing, developing and commercializing our approach.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-152
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Trotting robots reveal emergence of animal gait transitions
A four-legged robot trained with machine learning by EPFL researchers has learned to avoid falls by spontaneously switching between walking, trotting, and pronking – a milestone for roboticists as well…
Innovation promises to prevent power pole-top fires
Engineers in Australia have found a new way to make power-pole insulators resistant to fire and electrical sparking, promising to prevent dangerous pole-top fires and reduce blackouts. Pole-top fires pose…
Possible alternative to antibiotics produced by bacteria
Antibacterial substance from staphylococci discovered with new mechanism of action against natural competitors. Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers…
